DNA Methylation and Arsenic-associated Urothelial Carcinoma

NCT ID: NCT01360723

Last Updated: 2011-05-27

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 600 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-05-31

Brief Summary

The investigators previously pointed out the significant association between urinary arsenic profiles and urothelial carcinoma (UC) risk through a 12-year follow-up study. Further, the investigators observed the increased UC risk in people with lower plasma folate and higher homocysteine than those with higher plasma folate and lower homocysteine in 2010. S-adenosylmethionine (SAM) is one factor included in one-carbon metabolism pathway and is the main donor of methyl group in cells. The ratio of SAM and its metabolite S-adenosylhomocysteine (SAH) not only reflected the intake level of dietary folate but also demonstrated the extent of global DNA methylation. These factors might play important roles in UC carcinogenesis. The investigators would expect to take three years to explore the interactions among global DNA methylation, one-carbon metabolic pathway factors, urinary arsenic profiles, the polymorphisms and haplotype of Glycine N-methyltransferase (GNMT) and UC. In the first year, the investigators would measure the levels of plasma folate, homocysteine, SAM and SAH and evaluate the associations between these factors and UC risk. In the second year, the investigators would set up the method of immunohistochemistry stain and compare the differences between the global DNA methylation from bladder tissues and blood. In the last year, this investigators would analyze the GNMT gene polymorphism and haplotype variation. At the same time, the investigators would explore the impact of GNMT genetic variation and global DNA methylation on UC risk. Based on the results from our research, the investigators might propose that the decreased ratio of SAM/SAH resulted in UC risk increased. This mechanism might be through the changed levels of urinary arsenic profiles and global DNA methylation.

Conditions

Urothelial Carcinoma

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

urothelial carcinoma

Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.

No interventions assigned to this group

Healthy controls group

Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of urothelial carcinoma
• The voluntary of participating the study

Exclusion Criteria

• Age smaller than 20 years
• Pregnant women
• Not willing to participate the study because of their personal reasons

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

China Medical University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Department of Urology

Principal Investigators

Chi-Jung Chung, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Health risk Management, China Medical University

Locations

Department of Urology, China Medical University Hospital

Taichung, , Taiwan

Site Status: RECRUITING

Countries

Taiwan

Central Contacts

Chao-Hsiang Chang, PhD

Role: CONTACT

urology8395@yahoo.com.tw

886-4-22052121 ext. 4439

Facility Contacts

Chao-Hsiang Chuang, PhD

Role: primary

urology8395@yahoo.com.tw

886-4-22052121 ext. 4439

Other Identifiers

DMR100-IRB-080

Identifier Type: -

Identifier Source: org_study_id